MODERNA SUBMITS REGULATORY APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR ITS UPDATED COVID-19 VACCINE
The filing follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Jul 23
The filing follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines
03 Jul 23
Hyrimoz HCF is approved in the US to treat indications including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis,…
03 Jul 23
The newly secured funding will be utilised to expand operations and further advance the development of its groundbreaking…
03 Jul 23
Cyltezo is the only adalimumab biosimilar with Phase III comparative clinical studies in rheumatoid arthritis, plaque psoriasis and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Jun 23
Under the NEURii collaboration, partners will pool their expertise in therapeutics, technology development and commercialisation, health data management…
30 Jun 23
Lilly will purchase all the outstanding shares of Sigilon at a price of $14.92 per share, which amounts…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Jun 23
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, participated in today's…
30 Jun 23
Posaconazole injection is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high…
28 Jun 23
The US FDA granted Fast Track designation to NgG, since gonorrhoea is recognised as an urgent unmet medical…
28 Jun 23
Topline results from the follicular lymphoma cohort demonstrated an ORR of 82%, which surpassed the protocol prespecified threshold…